Immunotherapy Advances
@imtadvances.bsky.social
#OpenAccess journal covering the translational pipeline for #immunotherapy 🎯Included in WoS, PubMed & Scopus
🦠 DC3s in solid tumours can prime T cells and influence outcomes—boosting survival in some cancers, but promoting immunosuppression in others.
👉 https://bit.ly/3T2blRg
##Immunotherapy #CancerImmunology
👉 https://bit.ly/3T2blRg
##Immunotherapy #CancerImmunology
November 7, 2025 at 11:10 AM
🦠 DC3s in solid tumours can prime T cells and influence outcomes—boosting survival in some cancers, but promoting immunosuppression in others.
👉 https://bit.ly/3T2blRg
##Immunotherapy #CancerImmunology
👉 https://bit.ly/3T2blRg
##Immunotherapy #CancerImmunology
🔬 First head-to-head comparison of nuclear imaging for tumour CD8⁺ T cells shows [⁸⁹Zr]Zr-anti-CD8-IgG2a(silent) & [⁸⁹Zr]Zr-OT-I track T-cell infiltration & migration, aiding immunotherapy strategies.
👉 https://bit.ly/4ncWCzv
##Immunotherapy #CD8Tcells #CancerResearch
👉 https://bit.ly/4ncWCzv
##Immunotherapy #CD8Tcells #CancerResearch
November 6, 2025 at 10:40 AM
🔬 First head-to-head comparison of nuclear imaging for tumour CD8⁺ T cells shows [⁸⁹Zr]Zr-anti-CD8-IgG2a(silent) & [⁸⁹Zr]Zr-OT-I track T-cell infiltration & migration, aiding immunotherapy strategies.
👉 https://bit.ly/4ncWCzv
##Immunotherapy #CD8Tcells #CancerResearch
👉 https://bit.ly/4ncWCzv
##Immunotherapy #CD8Tcells #CancerResearch
From CAR-NK cells to checkpoint inhibitors, Blunt & Khakoo review how boosting NK-cell function could transform cancer therapy.
🔓 Open access: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
🔓 Open access: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
October 22, 2025 at 3:30 PM
From CAR-NK cells to checkpoint inhibitors, Blunt & Khakoo review how boosting NK-cell function could transform cancer therapy.
🔓 Open access: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
🔓 Open access: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
New study shows switching between Humira® and AVT02 in chronic plaque psoriasis does not alter cellular immunogenicity.
Novel EVCIA approach confirms comparable T cell responses, supporting interchangeability.
🔗 Open access: https://bit.ly/3J8pESs
#Immunology #Psoriasis
Novel EVCIA approach confirms comparable T cell responses, supporting interchangeability.
🔗 Open access: https://bit.ly/3J8pESs
#Immunology #Psoriasis
October 18, 2025 at 10:13 AM
New study shows switching between Humira® and AVT02 in chronic plaque psoriasis does not alter cellular immunogenicity.
Novel EVCIA approach confirms comparable T cell responses, supporting interchangeability.
🔗 Open access: https://bit.ly/3J8pESs
#Immunology #Psoriasis
Novel EVCIA approach confirms comparable T cell responses, supporting interchangeability.
🔗 Open access: https://bit.ly/3J8pESs
#Immunology #Psoriasis
Tracking CD8+ T cells in tumours is key for immunotherapy research. Our new study compares nuclear imaging methods to see which best reflects T cell infiltration.
🔗 Open access: https://bit.ly/4ncWCzv
#Immunotherapy #CD8TCells #CancerResearch
🔗 Open access: https://bit.ly/4ncWCzv
#Immunotherapy #CD8TCells #CancerResearch
October 17, 2025 at 10:23 AM
Tracking CD8+ T cells in tumours is key for immunotherapy research. Our new study compares nuclear imaging methods to see which best reflects T cell infiltration.
🔗 Open access: https://bit.ly/4ncWCzv
#Immunotherapy #CD8TCells #CancerResearch
🔗 Open access: https://bit.ly/4ncWCzv
#Immunotherapy #CD8TCells #CancerResearch
🏆Following last week's exciting #NobelPrize announcement, the BSI journals have created a new virtual issue.
🔎Check it out for must-read articles on peripheral immune tolerance, including a paper from Nobel Laureate Shimon Sakaguchi: immunology.org/publications...
🔎Check it out for must-read articles on peripheral immune tolerance, including a paper from Nobel Laureate Shimon Sakaguchi: immunology.org/publications...
The 2025 Nobel Prize Virtual Issue | British Society for Immunology
immunology.org
October 13, 2025 at 2:33 PM
🏆Following last week's exciting #NobelPrize announcement, the BSI journals have created a new virtual issue.
🔎Check it out for must-read articles on peripheral immune tolerance, including a paper from Nobel Laureate Shimon Sakaguchi: immunology.org/publications...
🔎Check it out for must-read articles on peripheral immune tolerance, including a paper from Nobel Laureate Shimon Sakaguchi: immunology.org/publications...
🧬 New in Immunotherapy Advances:
Cytokine-induced memory-like NK cells + Tafasitamab show strong efficacy against B-cell ALL, boosting cytotoxicity & survival in vivo.
Open Access 👉 https://bit.ly/48oztXa
##Immunotherapy #NKcells
Cytokine-induced memory-like NK cells + Tafasitamab show strong efficacy against B-cell ALL, boosting cytotoxicity & survival in vivo.
Open Access 👉 https://bit.ly/48oztXa
##Immunotherapy #NKcells
October 9, 2025 at 2:01 PM
🧬 New in Immunotherapy Advances:
Cytokine-induced memory-like NK cells + Tafasitamab show strong efficacy against B-cell ALL, boosting cytotoxicity & survival in vivo.
Open Access 👉 https://bit.ly/48oztXa
##Immunotherapy #NKcells
Cytokine-induced memory-like NK cells + Tafasitamab show strong efficacy against B-cell ALL, boosting cytotoxicity & survival in vivo.
Open Access 👉 https://bit.ly/48oztXa
##Immunotherapy #NKcells
🧬 Low MHC-I expression can help tumours evade the immune system.
Discover strategies to boost MHC-I and improve immunotherapy in paediatric and adult cancers. 🔬
Read: https://bit.ly/45vtfmp
#Immunotherapy #CancerResearch #MHCI
Discover strategies to boost MHC-I and improve immunotherapy in paediatric and adult cancers. 🔬
Read: https://bit.ly/45vtfmp
#Immunotherapy #CancerResearch #MHCI
September 29, 2025 at 12:55 PM
🧬 Low MHC-I expression can help tumours evade the immune system.
Discover strategies to boost MHC-I and improve immunotherapy in paediatric and adult cancers. 🔬
Read: https://bit.ly/45vtfmp
#Immunotherapy #CancerResearch #MHCI
Discover strategies to boost MHC-I and improve immunotherapy in paediatric and adult cancers. 🔬
Read: https://bit.ly/45vtfmp
#Immunotherapy #CancerResearch #MHCI
💡 Tumour-reactive plasma cells are emerging as powerful players in cancer immunotherapy!
Explore their role in antibody-based, personalized treatments. 🔬
Read: https://bit.ly/3SVZsMC
#Immunotherapy #CancerResearch #PlasmaCells
Explore their role in antibody-based, personalized treatments. 🔬
Read: https://bit.ly/3SVZsMC
#Immunotherapy #CancerResearch #PlasmaCells
September 26, 2025 at 10:56 AM
💡 Tumour-reactive plasma cells are emerging as powerful players in cancer immunotherapy!
Explore their role in antibody-based, personalized treatments. 🔬
Read: https://bit.ly/3SVZsMC
#Immunotherapy #CancerResearch #PlasmaCells
Explore their role in antibody-based, personalized treatments. 🔬
Read: https://bit.ly/3SVZsMC
#Immunotherapy #CancerResearch #PlasmaCells
💥Open Access review: NK cells as cancer fighters!
From CAR-NK cells to checkpoint inhibitors, explore cutting-edge strategies to harness NK-cell immunity. 🔬
Read: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
From CAR-NK cells to checkpoint inhibitors, explore cutting-edge strategies to harness NK-cell immunity. 🔬
Read: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
September 25, 2025 at 3:16 PM
💥Open Access review: NK cells as cancer fighters!
From CAR-NK cells to checkpoint inhibitors, explore cutting-edge strategies to harness NK-cell immunity. 🔬
Read: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
From CAR-NK cells to checkpoint inhibitors, explore cutting-edge strategies to harness NK-cell immunity. 🔬
Read: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
Could CD200R blockade enhance PD-1 therapy?
A humanised mouse study found limited benefit in colorectal & lung cancer, but points to potential in CD200⁺ tumours.
🔗 https://bit.ly/4pdAtDw
#Immunotherapy #CancerResearch
A humanised mouse study found limited benefit in colorectal & lung cancer, but points to potential in CD200⁺ tumours.
🔗 https://bit.ly/4pdAtDw
#Immunotherapy #CancerResearch
September 23, 2025 at 10:13 AM
Could CD200R blockade enhance PD-1 therapy?
A humanised mouse study found limited benefit in colorectal & lung cancer, but points to potential in CD200⁺ tumours.
🔗 https://bit.ly/4pdAtDw
#Immunotherapy #CancerResearch
A humanised mouse study found limited benefit in colorectal & lung cancer, but points to potential in CD200⁺ tumours.
🔗 https://bit.ly/4pdAtDw
#Immunotherapy #CancerResearch
Exploring the role of DC3s in solid tumours! These dendritic cells can boost anti-tumour immunity or contribute to immunosuppression depending on the TME.
Discover their potential for targeted therapies 👉 https://bit.ly/3T2blRg
#EMDS2025 #Immunotherapy #CancerResearch
Discover their potential for targeted therapies 👉 https://bit.ly/3T2blRg
#EMDS2025 #Immunotherapy #CancerResearch
September 19, 2025 at 12:03 PM
Exploring the role of DC3s in solid tumours! These dendritic cells can boost anti-tumour immunity or contribute to immunosuppression depending on the TME.
Discover their potential for targeted therapies 👉 https://bit.ly/3T2blRg
#EMDS2025 #Immunotherapy #CancerResearch
Discover their potential for targeted therapies 👉 https://bit.ly/3T2blRg
#EMDS2025 #Immunotherapy #CancerResearch
TAMs drive tumour progression, metastasis & therapy resistance.
Targeting their surface receptors may unlock new cancer immunotherapy strategies, insights for #EMDS2025
🔗 https://bit.ly/4i95qnm
Targeting their surface receptors may unlock new cancer immunotherapy strategies, insights for #EMDS2025
🔗 https://bit.ly/4i95qnm
September 17, 2025 at 10:15 AM
TAMs drive tumour progression, metastasis & therapy resistance.
Targeting their surface receptors may unlock new cancer immunotherapy strategies, insights for #EMDS2025
🔗 https://bit.ly/4i95qnm
Targeting their surface receptors may unlock new cancer immunotherapy strategies, insights for #EMDS2025
🔗 https://bit.ly/4i95qnm
Could JAK inhibitors be a treatment for STAT3 gain-of-function?
Study shows symptom improvement in patients with this rare immune disorder.
Read here🔗 https://bit.ly/4p7Vxer
#Immunotherapy
Study shows symptom improvement in patients with this rare immune disorder.
Read here🔗 https://bit.ly/4p7Vxer
#Immunotherapy
September 16, 2025 at 10:08 PM
Could JAK inhibitors be a treatment for STAT3 gain-of-function?
Study shows symptom improvement in patients with this rare immune disorder.
Read here🔗 https://bit.ly/4p7Vxer
#Immunotherapy
Study shows symptom improvement in patients with this rare immune disorder.
Read here🔗 https://bit.ly/4p7Vxer
#Immunotherapy
⏳ Last chance! Submit your research on immunotherapies for inborn errors of immunity to our Special Collection before the end of September.
Submit here: https://bit.ly/4p96dJA
##Immunology
Submit here: https://bit.ly/4p96dJA
##Immunology
September 16, 2025 at 10:55 AM
⏳ Last chance! Submit your research on immunotherapies for inborn errors of immunity to our Special Collection before the end of September.
Submit here: https://bit.ly/4p96dJA
##Immunology
Submit here: https://bit.ly/4p96dJA
##Immunology
It's the final day of Cancer Immunology: Advances & Therapeutic Application, don’t miss our journals manager Laura Franklin giving a talk at 11:00 AM today!
Learn more about publishing opportunities and journal initiatives.
##CancerImmunology #Immunotherapy
Learn more about publishing opportunities and journal initiatives.
##CancerImmunology #Immunotherapy
September 12, 2025 at 8:49 AM
It's the final day of Cancer Immunology: Advances & Therapeutic Application, don’t miss our journals manager Laura Franklin giving a talk at 11:00 AM today!
Learn more about publishing opportunities and journal initiatives.
##CancerImmunology #Immunotherapy
Learn more about publishing opportunities and journal initiatives.
##CancerImmunology #Immunotherapy
Are you attending Cancer Immunology: Advances & Therapeutic Application and working on cancer vaccines?
Share your latest research in our Special Collection on global advances, personalised or off-the-shelf vaccines, clinical trials & more.
Submit here: https://bit.ly/4mPbW64
Share your latest research in our Special Collection on global advances, personalised or off-the-shelf vaccines, clinical trials & more.
Submit here: https://bit.ly/4mPbW64
September 11, 2025 at 9:15 AM
Are you attending Cancer Immunology: Advances & Therapeutic Application and working on cancer vaccines?
Share your latest research in our Special Collection on global advances, personalised or off-the-shelf vaccines, clinical trials & more.
Submit here: https://bit.ly/4mPbW64
Share your latest research in our Special Collection on global advances, personalised or off-the-shelf vaccines, clinical trials & more.
Submit here: https://bit.ly/4mPbW64
Attending Cancer Immunology: Advances & Therapeutic Application?
Come and visit us at our booth to learn more about our journals, upcoming special collections, and opportunities to publish! #CancerImmunology #Immunology
Come and visit us at our booth to learn more about our journals, upcoming special collections, and opportunities to publish! #CancerImmunology #Immunology
September 10, 2025 at 11:15 AM
Attending Cancer Immunology: Advances & Therapeutic Application?
Come and visit us at our booth to learn more about our journals, upcoming special collections, and opportunities to publish! #CancerImmunology #Immunology
Come and visit us at our booth to learn more about our journals, upcoming special collections, and opportunities to publish! #CancerImmunology #Immunology
NLRP3 inflammasome activation in sensory neurons drives chronic inflammatory & osteoarthritis pain.
Blocking this pathway may offer a route to new treatments.
Read more🔗 https://bit.ly/3UX7Tbz
#ChronicPain #Immunology
Blocking this pathway may offer a route to new treatments.
Read more🔗 https://bit.ly/3UX7Tbz
#ChronicPain #Immunology
September 8, 2025 at 9:38 AM
NLRP3 inflammasome activation in sensory neurons drives chronic inflammatory & osteoarthritis pain.
Blocking this pathway may offer a route to new treatments.
Read more🔗 https://bit.ly/3UX7Tbz
#ChronicPain #Immunology
Blocking this pathway may offer a route to new treatments.
Read more🔗 https://bit.ly/3UX7Tbz
#ChronicPain #Immunology
Working on targeted therapies for inborn errors of immunity?
Our Special Collection on genetics-guided immunotherapy closes at the end of this month, submit your research today!
Learn more: https://bit.ly/4p96dJA
Our Special Collection on genetics-guided immunotherapy closes at the end of this month, submit your research today!
Learn more: https://bit.ly/4p96dJA
September 6, 2025 at 10:18 AM
Working on targeted therapies for inborn errors of immunity?
Our Special Collection on genetics-guided immunotherapy closes at the end of this month, submit your research today!
Learn more: https://bit.ly/4p96dJA
Our Special Collection on genetics-guided immunotherapy closes at the end of this month, submit your research today!
Learn more: https://bit.ly/4p96dJA
🚀 Going viral against #Glioblastoma!
Discover how oncolytic viruses are reshaping the immune landscape of GBM, boosting therapy response & offering new hope.
Open Access 👉 https://bit.ly/3UMBhkw #Immunotherapy #CancerResearch
Discover how oncolytic viruses are reshaping the immune landscape of GBM, boosting therapy response & offering new hope.
Open Access 👉 https://bit.ly/3UMBhkw #Immunotherapy #CancerResearch
September 5, 2025 at 11:03 AM
🚀 Going viral against #Glioblastoma!
Discover how oncolytic viruses are reshaping the immune landscape of GBM, boosting therapy response & offering new hope.
Open Access 👉 https://bit.ly/3UMBhkw #Immunotherapy #CancerResearch
Discover how oncolytic viruses are reshaping the immune landscape of GBM, boosting therapy response & offering new hope.
Open Access 👉 https://bit.ly/3UMBhkw #Immunotherapy #CancerResearch
High-affinity TCR bispecific (ImmTAC®) redirects T cells to efficiently kill PRAME+ tumor cells across multiple cancers. Combination with PD-1 blockade may enhance activity.
By Ribeiro et al.
🔗 https://bit.ly/40o5kT8
##Immunotherapy #CancerResearch #PRAME
By Ribeiro et al.
🔗 https://bit.ly/40o5kT8
##Immunotherapy #CancerResearch #PRAME
September 3, 2025 at 4:42 PM
High-affinity TCR bispecific (ImmTAC®) redirects T cells to efficiently kill PRAME+ tumor cells across multiple cancers. Combination with PD-1 blockade may enhance activity.
By Ribeiro et al.
🔗 https://bit.ly/40o5kT8
##Immunotherapy #CancerResearch #PRAME
By Ribeiro et al.
🔗 https://bit.ly/40o5kT8
##Immunotherapy #CancerResearch #PRAME
💉 During #ImmunisationAwarenessMonth, a timely reminder: mRNA COVID-19 vaccines (Pfizer & Moderna) remain highly effective at preventing hospitalisation (84–86%), even with variant challenges.
🔗 https://bit.ly/43rUWvP
##Vaccineswork #immunology
🔗 https://bit.ly/43rUWvP
##Vaccineswork #immunology
August 29, 2025 at 12:39 PM
💉 During #ImmunisationAwarenessMonth, a timely reminder: mRNA COVID-19 vaccines (Pfizer & Moderna) remain highly effective at preventing hospitalisation (84–86%), even with variant challenges.
🔗 https://bit.ly/43rUWvP
##Vaccineswork #immunology
🔗 https://bit.ly/43rUWvP
##Vaccineswork #immunology
💉 Cancer vaccines are regaining momentum with advances in neoantigen science, tumour mutational burden & mRNA technology.
A deeper understanding of dendritic cells and immune mechanisms is key to unlocking their full potential. 🚀
##ImmunisationAwarenessMonth
🔗 https://bit.ly/4cefxGm
A deeper understanding of dendritic cells and immune mechanisms is key to unlocking their full potential. 🚀
##ImmunisationAwarenessMonth
🔗 https://bit.ly/4cefxGm
August 28, 2025 at 5:18 PM
💉 Cancer vaccines are regaining momentum with advances in neoantigen science, tumour mutational burden & mRNA technology.
A deeper understanding of dendritic cells and immune mechanisms is key to unlocking their full potential. 🚀
##ImmunisationAwarenessMonth
🔗 https://bit.ly/4cefxGm
A deeper understanding of dendritic cells and immune mechanisms is key to unlocking their full potential. 🚀
##ImmunisationAwarenessMonth
🔗 https://bit.ly/4cefxGm
Why are paediatric tumours less responsive to immunotherapy?
One reason: MHC-I downregulation. Restoring it could make tumour cells visible again to CD8 T cells.
🔗 https://bit.ly/45vtfmp
One reason: MHC-I downregulation. Restoring it could make tumour cells visible again to CD8 T cells.
🔗 https://bit.ly/45vtfmp
August 22, 2025 at 5:30 PM
Why are paediatric tumours less responsive to immunotherapy?
One reason: MHC-I downregulation. Restoring it could make tumour cells visible again to CD8 T cells.
🔗 https://bit.ly/45vtfmp
One reason: MHC-I downregulation. Restoring it could make tumour cells visible again to CD8 T cells.
🔗 https://bit.ly/45vtfmp